A phase III placebo-controlled study of eftilagimod alfa plus pembrolizumab and chemotherapy in metastatic non-small cell lung cancer.
- DOI
- 10.1080/14796694.2025.2597404
- Published
- 2025 Dec
- Container
- Future oncology (London, England)
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1080/14796694.2025.2597404,
title = {A phase III placebo-controlled study of eftilagimod alfa plus pembrolizumab and chemotherapy in metastatic non-small cell lung cancer.},
author = {O'Byrne K and Esteban E and Lee CL and Hegmane A and Volovat C and Lo Russo G and Ziogas D and Atmaca A and Sebastian M and Majem M},
year = {2025},
journal = {Future oncology (London, England)},
doi = {10.1080/14796694.2025.2597404},
url = {https://doi.org/10.1080/14796694.2025.2597404}
}RIS
TY - JOUR TI - A phase III placebo-controlled study of eftilagimod alfa plus pembrolizumab and chemotherapy in metastatic non-small cell lung cancer. AU - O'Byrne K AU - Esteban E AU - Lee CL AU - Hegmane A AU - Volovat C AU - Lo Russo G AU - Ziogas D AU - Atmaca A AU - Sebastian M AU - Majem M PY - 2025 JO - Future oncology (London, England) DO - 10.1080/14796694.2025.2597404 UR - https://doi.org/10.1080/14796694.2025.2597404 ER -
APA
K, O., E, E., CL, L., A, H., C, V., G, L. R., D, Z., A, A., M, S., & M, M. (2025). A phase III placebo-controlled study of eftilagimod alfa plus pembrolizumab and chemotherapy in metastatic non-small cell lung cancer.. Future oncology (London, England). https://doi.org/10.1080/14796694.2025.2597404
Source records
- pubmed · retrieved 2026-09-27T10:31:02.374Z
- europe-pmc · retrieved 2026-09-27T10:31:02.395Z